Otros idiomas Foghorn Therapeutics Inc.

Acciones

FHTX

US3441741077

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
5,83 ^USD	+0,52 %		+3,37 %	-9,61 %

20/05	Foghorn Therapeutics fija el precio de una oferta de 110 millones de dólares en acciones y garantías prefinanciadas	MT
06/05	Foghorn Therapeutics Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants	20/05
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Transcript : Foghorn Therapeutics Inc. - Special Call	09/04
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08/01
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	05/01
Foghorn Therapeutics Says CFO is Leaving; Shares Fall After-Hours	03/01
FOGHORN THERAPEUTICS INC. : Morgan Stanley maintient son opinion neutre	13/11
Foghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference	04/10/23
Foghorn Therapeutics Begins Phase 1 Combination Study of FHD-286 to Treat AML	31/08/23
Foghorn Therapeutics Inc. Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed And/Or Refractory AML	31/08/23
Insider Sell: Foghorn Therapeutics	18/08/23
Foghorn Therapeutics Inc Announces Executive Changes	08/08/23
Foghorn Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/08/23
Pfizer y Flagship Pioneering invertirán 100 millones de dólares en el descubrimiento de fármacos	18/07/23
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery	18/07/23
FOGHORN THERAPEUTICS INC. : Morgan Stanley confirme sa recommandation neutre	06/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Foghorn Therapeutics Inc.

Acciones

FHTX

US3441741077

Otros idiomas

Filtros